

FULL VALUE OF VACCINE ASSESSMENT

GROUP B STREPTOCOCCUS VACCINE

**POLICY AND
IMPLEMENTATION
ISSUES**



**World Health
Organization**

FULL VALUE OF VACCINE ASSESSMENT

GROUP B STREPTOCOCCUS VACCINE

**POLICY AND
IMPLEMENTATION
ISSUES**



**World Health
Organization**

Group B streptococcus vaccine: full value of vaccine assessment. Policy and implementation issues

ISBN 978 92 4 002251 5 (electronic version)

ISBN 978 92 4 002252 2 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Group B streptococcus vaccine: full value of vaccine assessment. Policy and implementation issues. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/about/policies/publishing/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover photo credit: Louis Leeson/LSHTM2017

CONTENTS

Acknowledgements.....	vi
Abbreviations and acronyms	vii
Executive summary.....	ix
Policy formulation at the national level.....	ix
Options for service delivery.....	ix
Factors affecting uptake of vaccination and measures to address them.....	x
Monitoring the coverage, impact and safety of vaccination.....	x
1. INTRODUCTION	1
2. OBJECTIVES	3
3. METHODS	4
3.1 Limitations.....	4
4. ESTABLISHING NATIONAL POLICY FOR GBS VACCINATION	5
4.1 Existing level of awareness of GBS disease and its prioritization.....	5
4.2 Policy-relevant evidence to enable the vaccine to be optimally prioritized for introduction.....	11
5. SERVICE DELIVERY	15
5.1 Mode of delivery of vaccination to pregnant women.....	15
5.2 Opportunities and challenges for the integration of ANC and immunization services.....	18
5.3 Expected coverage with GBS vaccination delivered through ANC.....	20
6. ACCEPTABILITY AND DEMAND FOR MATERNAL IMMUNIZATION	22
6.1 Factors that influence the uptake of vaccination during pregnancy.....	22
6.2 Strategies and approaches to improve demand and acceptance.....	29
6.3 Existing tools for improving uptake of vaccination.....	30

6.4 Availability of data on adverse pregnancy outcomes.....	32
6.5 Conclusion on data availability for risk communication.....	34
7. MONITORING AND EVALUATION	35
7.1 Monitoring vaccination coverage.....	35
7.2 Monitoring the impact of GBS vaccination.....	38
7.3 Safety monitoring.....	40
8. CONCLUSIONS	43
8.1 Policy formulation at the national level.....	43
8.2 Options for service delivery.....	43
8.3 Factors affecting uptake of vaccination and measures to address them.....	44
8.4 Monitoring the coverage, impact and safety of vaccination.....	44
References.....	46
Annex 1. Technical Working Group of Workstream 3.....	57
Annex 2. Stakeholder survey on Group B streptococcal (GBS) disease and vaccine prioritization.....	58

List of tables

Table 1. Survey response rates by categories.....	6
Table 2. Maternal immunization service delivery responsibilities at the national level (data from an online survey in 95 LMICs).....	16
Table 3. Factors that influence the uptake of antenatal care (ANC): summary of findings.....	23
Table 4. The 11 steps of the TIP approach.....	32

List of figures

Fig. 1: Respondents by area of expertise and country income level (World Bank classification).....	7
Fig. 2: Perception that GBS disease is a public health problem and existence of national policy to prevent neonatal GBS disease.....	8
Fig. 3: Perceived level of awareness of pregnant women of GBS disease (as reported by health professionals and policy-makers).....	9
Fig. 4: Respondents' view of GBS vaccine prioritization and of perceived acceptance of GBS vaccination among pregnant women (as reported by health professionals and policy-makers).....	10
Fig. 5: Respondents view of barriers to inclusion of GBS vaccination in NIPs.....	11
Fig. 6: Strategies to deliver maternal tetanus vaccination (data from 90 LMICs).....	16
Fig. 7: Coverage with four ANC visits during pregnancy (ANC4).....	17
Fig. 8: Socioecological model for improving vaccination uptake during pregnancy (adapted from UNICEF's model for communication for development and TIPFlu).....	31
Fig. 9: The seven Ps of social marketing.....	31
Fig. 10: Flow of immunization data in most LMICs.....	37

Acknowledgements

This report was developed by Thomas Cherian and Carsten Mantel, MMGH Consulting, and Philipp Lambach, WHO, with review and inputs from a Technical Working Group and the projects' overall Scientific Advisory Group.

Technical Working Group: Flor M. Munoz, Martina Lukong Baye, Lumbwe Chola, Michelle Giles, Asma Khalil, Elizabeth Mason, Sonja Merten, Baoping Yang.

Scientific Advisory Group: Elizabeth Mason, Martina Lukong Baye, Lumbwe Chola, Paul T. Heath, Margaret Ip, Shabir A. Madhi, Nicholas Kassebaum, Asma Khalil, Kirsty Le Doare, Flor M. Munoz, Maarten Postma, Samir Saha, Stephanie Schrag. Baoping Yang was consulted as representative of the WHO Immunization Practices Advisory Committee (IPAC).

Consultants/observers: Jessica Fleming, Will Hausdorff, Melissa Malhame, Stefano Malvoti, Clint Pecenka, Caroline Trotter.

Additional experts: Martin Friede, Tanja Cernuschi, Adam Cohen, Maria Carolina Danovaro Alfaro, Theresa Diaz, Birgitte Giersing, Bronner Goncalves, Tracey Goodman, Raymond Hutubessy, Mark Jit, Melissa Ko, Joy Lawn, Will Gardner, Allisyn Moran, Laura Nic Lochlainn, Proma Paul, Marc Perut, Simon Procter, Messeret Shibeshi, Johan Vekemans.

Financial support for the development and pilot-testing of this report is provided through the Bill & Melinda Gates Foundation, which provides financial support to the World Health Organization Immunization, Vaccines and Biologicals department (INV-1175247).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23528

